

Basel, 16 September 2008

New data confirms Avastin as the only biologic to demonstrate overall survival when used first-line in metastatic colorectal cancer patients with K-RAS (wild-type) gene status

Basel, September 16, 2008: Avastin (bevacizumab) remains the only biologic to provide overall survival (OS) benefit when used as first-line treatment in combination with chemotherapy for patients with K-Ras wild type metastatic colorectal cancer (mCRC). Avastin's strong position was confirmed today following new data from a cetuximab [Erbix] study presented at the 33rd Congress of the European Society for Medical Oncology (ESMO). "K-Ras wild-type" describes the normal gene status seen in around 60% of colorectal cancer patients where the K-Ras oncogene has not mutated.

This confirmation of Avastin's survival benefit is important because overall survival is of key importance for patients with advanced colorectal cancer.

The data presented came from a cetuximab study called the CRYSTAL trial which showed that cetuximab in combination with chemotherapy failed to deliver a significant overall survival benefit in either the general population or in patients tested for K-Ras status. In contrast, an earlier analysis of Avastin first-line in combination with chemotherapy achieved significant overall survival for over two years (27.7 months) for patients with mCRC with K-Ras wild-type. Avastin therefore remains the best treatment option for patients with mCRC, regardless of oncogene mutations (e.g. K-Ras).

"Extending the lives of my patients remains a key goal for me as a treating physician" said Dr Mark Kozloff, Associate Professor, Department of Oncology, University of Chicago, School of Medicine, US. "Avastin is the only biologic in combination with chemotherapy which allows us to achieve this essential outcome and should therefore be used first-line in the majority of patients with metastatic colorectal cancer regardless of their K-Ras status".

Main findings from CRYSTAL were:

- There was no statistical difference in overall survival (OS) in the K-Ras wild-type population – the study

was negative for this secondary endpoint (24.9 vs. 21.0 months in the cetuximab and control arm respectively) (HR 0.84, p 0.22)

- There was no statistical difference in OS in the general study population – the study therefore failed to meet this key secondary endpoint (19.9 vs. 18.6 months in the cetuximab and control arm respectively) (HR 0.93, p 0.30)

Main outcomes from pivotal Avastin 2107 study which demonstrated Avastin's superior K-Ras data:

- Avastin provides a statistically significant OS advantage in the K-Ras wild-type population (27.7 vs. 17.6 months in the Avastin and Control arm respectively) (HR 0.58, p 0.04)
- Avastin also provides statistically significant improvements in the time patients live without their disease worsening for both K-Ras wild-type (PFS improved by 82%, from 7.4 to 13.5 months, hazard ratio: 0.44, $p < 0.0001$) and K-Ras mutant patients (PFS improved by 69%, from 5.5 to 9.4 months, hazard ratio: 0.41, $p = 0.0008$).
- Avastin provides a statistically significant gain in OS in the general population (20.3 vs. 15.6 months in the Avastin and control arm respectively) (HR 0.66, $p < 0.001$)
- The overall survival benefit of Avastin has been confirmed in two large community-based studies (First BEAT / BRiTE), including some 4,000 patients

In January 2008, Avastin received a broad label in the EU allowing it to be used in combination with fluoropyrimidine-based chemotherapy for first and later treatment lines in patients with mCRC. This means that virtually all patients with metastatic colorectal cancer have access to Avastin's benefits.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group

employs about 80,000 people. Additional information is available on the Internet at www.roche.com.

All trademarks used or mentioned in this release are legally protected.

Additional information

www.avastin-info.com

www.Roche.com

www.thenewsmarket.com (video clips about Avastin in broadcast standard, free of charge)

Roche Group Media Relations

Phone: +41 -61 688 8888 / e-mail: basel.mediaoffice@roche.com

- Daniel Piller (Head)
- Alexander Klauser
- Martina Rupp
- Claudia Schmitt
- Nina Schwab-Hautzinger